Unleashing the immune response to treat cancer

Unleash Immuno Oncolytics, is an immune-oncology company developing oncolytic virus immunotherapy products to treat cancer

Our lead product, UIO-512, is a patent-protected oncolytic virus designed to target both malignant cells and tumor-associated stroma cells, facilitating a lateralized infection. This targeted viral infection is recognized by the immune system, which unleashes an enhanced immune response to attack the tumor

Unleash’s lead program is a differentiated immune-oncology treatment that has already shown promising proof of concept results in animal models and human explants of different types of gynecological cancer and melanoma

We are currently planning IND-enabling GMP manufacturing, pre-clinical, toxicology and biodistribution studies of UIO-512 in our two leading indications: ovarian cancer and melanoma